JP2005529163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005529163A5 JP2005529163A5 JP2004510806A JP2004510806A JP2005529163A5 JP 2005529163 A5 JP2005529163 A5 JP 2005529163A5 JP 2004510806 A JP2004510806 A JP 2004510806A JP 2004510806 A JP2004510806 A JP 2004510806A JP 2005529163 A5 JP2005529163 A5 JP 2005529163A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- pharmaceutical preparation
- decitabine
- pharmaceutical formulation
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 45
- 239000000825 pharmaceutical preparation Substances 0.000 claims 36
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 27
- 229960003603 decitabine Drugs 0.000 claims 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 22
- 239000002904 solvent Substances 0.000 claims 17
- 239000002202 Polyethylene glycol Substances 0.000 claims 13
- 229920001223 polyethylene glycol Polymers 0.000 claims 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 12
- 239000003085 diluting agent Substances 0.000 claims 12
- 239000002535 acidifier Substances 0.000 claims 11
- 235000011187 glycerol Nutrition 0.000 claims 11
- 239000007787 solid Substances 0.000 claims 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- 229920000858 Cyclodextrin Polymers 0.000 claims 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 6
- 235000010323 ascorbic acid Nutrition 0.000 claims 6
- 239000011668 ascorbic acid Substances 0.000 claims 6
- 229960005070 ascorbic acid Drugs 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 4
- -1 dextrox Chemical compound 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 150000007522 mineralic acids Chemical group 0.000 claims 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 2
- 235000015165 citric acid Nutrition 0.000 claims 2
- 239000002274 desiccant Substances 0.000 claims 2
- 229960005223 diatrizoic acid Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 235000019253 formic acid Nutrition 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 239000011976 maleic acid Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229910017604 nitric acid Inorganic materials 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 235000006408 oxalic acid Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- 239000011975 tartaric acid Substances 0.000 claims 2
- 235000002906 tartaric acid Nutrition 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003125 aqueous solvent Substances 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 229960004853 betadex Drugs 0.000 claims 1
- 239000012620 biological material Substances 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000011259 mixed solution Substances 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/164,276 | 2002-06-05 | ||
| US10/164,276 US6982253B2 (en) | 2002-06-05 | 2002-06-05 | Liquid formulation of decitabine and use of the same |
| PCT/US2003/017293 WO2003103687A1 (en) | 2002-06-05 | 2003-05-30 | Liquid formulation of decitabine and use of the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005529163A JP2005529163A (ja) | 2005-09-29 |
| JP2005529163A5 true JP2005529163A5 (https=) | 2006-06-29 |
| JP5129922B2 JP5129922B2 (ja) | 2013-01-30 |
Family
ID=29710172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004510806A Expired - Lifetime JP5129922B2 (ja) | 2002-06-05 | 2003-05-30 | デシタビンの液体製剤及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US6982253B2 (https=) |
| EP (1) | EP1509233A4 (https=) |
| JP (1) | JP5129922B2 (https=) |
| AU (1) | AU2003249680C9 (https=) |
| CA (1) | CA2488108A1 (https=) |
| WO (1) | WO2003103687A1 (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US6998391B2 (en) * | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| US20040162263A1 (en) * | 2002-10-31 | 2004-08-19 | Supergen, Inc., A Delaware Corporation | Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
| US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
| US20050059682A1 (en) * | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
| WO2005060981A2 (en) * | 2003-12-19 | 2005-07-07 | Schering Corporation | Pharmaceutical compositions |
| US7878899B2 (en) * | 2004-08-06 | 2011-02-01 | Labtronix Concept Inc. | Method and system for providing a tournament handicap feature |
| US20060063735A1 (en) * | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| AU2005289513B2 (en) * | 2004-09-17 | 2012-04-05 | Astex Pharmaceuticals, Inc. | Salts of decitabine |
| US20060069060A1 (en) * | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| US20060128654A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| WO2007019232A2 (en) * | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| US7700567B2 (en) * | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| US20070105792A1 (en) * | 2005-11-04 | 2007-05-10 | Dimartino Jorge F | Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases |
| US20070117776A1 (en) * | 2005-11-04 | 2007-05-24 | John Lyons | Low Dose Therapy Of DNA Methylation Inhibitors |
| EP2007370B1 (en) * | 2006-03-31 | 2013-12-18 | Erasmus University Medical Center Rotterdam | Novel composition for tumor growth control |
| CA2674865A1 (en) * | 2007-01-15 | 2008-07-24 | Santen Pharmaceutical Co., Ltd. | Indole derivative having i.kappa.b kinase .beta. inhibitory activity |
| CA2590048C (en) * | 2007-05-23 | 2013-07-16 | Institut National De La Recherche Scientifique | Cytosine nucleoside analogs and isoflavones and uses thereof |
| US20090075920A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched decitabine |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| DE102007050165B4 (de) * | 2007-10-19 | 2010-06-17 | Stiftung Tierärztliche Hochschule Hannover | Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung |
| US8445529B2 (en) * | 2008-07-14 | 2013-05-21 | Santen Pharmaceutical Co., Ltd. | Indole derivative having, carbamoyl group, ureido group and substituted oxy group |
| CN101361718B (zh) * | 2008-09-26 | 2013-08-28 | 深圳万乐药业有限公司 | 稳定的地西他滨冻干制剂的制备方法 |
| AR074052A1 (es) | 2008-10-22 | 2010-12-22 | Array Biopharma Inc | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa |
| US8609631B2 (en) * | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
| JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| CN102475687B (zh) * | 2010-11-27 | 2014-01-29 | 山东新时代药业有限公司 | 一种地西他滨冻干粉针剂 |
| WO2012106299A1 (en) * | 2011-01-31 | 2012-08-09 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
| EP2750768B1 (en) * | 2011-08-30 | 2018-10-03 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
| HRP20181187T1 (hr) | 2012-04-04 | 2018-09-21 | Halozyme, Inc. | Kombinirana terapija s hijaluronidazom i taksanom koji ciljano djeluje na tumor |
| US20140005148A1 (en) * | 2012-06-29 | 2014-01-02 | Coldstream Laboratories Inc. | Stable liquid formulations of nitrogen mustards |
| CN104768532B (zh) * | 2012-10-25 | 2017-11-28 | 费森尤斯卡比肿瘤学有限公司 | 5‑氮杂‑2’脱氧胞苷的稳定的药物组合物 |
| WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| WO2014194296A1 (en) * | 2013-05-30 | 2014-12-04 | Scidose, Llc | Formulations of vancomycin |
| CA2941632C (en) * | 2014-03-13 | 2023-10-24 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
| EP3291819A4 (en) * | 2015-05-05 | 2018-11-21 | The Regents of the University of California | Improved drug combinations for drug-resistant and drug-sensitive multiple myeloma |
| CN104887632B (zh) * | 2015-05-25 | 2017-10-24 | 连云港杰瑞药业有限公司 | 一种地西他滨冻干制剂的制备方法及其产品 |
| AU2016287585B2 (en) * | 2015-07-02 | 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
| DK3383406T3 (da) | 2015-12-03 | 2022-01-10 | Epidestiny Inc | Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin og anvendelser deraf |
| US10376559B2 (en) | 2016-01-15 | 2019-08-13 | Scidose, Llc | Formulations of vancomycin |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| ES2987474T3 (es) | 2016-04-04 | 2024-11-15 | Loxo Oncology Inc | Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida |
| ES2836222T3 (es) | 2016-05-18 | 2021-06-24 | Loxo Oncology Inc | Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| KR20200035438A (ko) | 2017-08-03 | 2020-04-03 | 오쓰까 세이야꾸 가부시키가이샤 | 약물 화합물 및 이의 정제 방법 |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| EP3801560A1 (en) * | 2018-05-25 | 2021-04-14 | Shilpa Medicare Limited | Pharmaceutical compositions of decitabine |
| JP7089603B2 (ja) | 2018-06-11 | 2022-06-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 眼疾患を治療するための脱メチル化 |
| US20230416294A1 (en) * | 2020-08-10 | 2023-12-28 | The Johns Hopkins University | Decitabine analogs for immunological and oncological therapy |
| EP4196106A1 (en) * | 2020-08-11 | 2023-06-21 | Auxilla Pharmaceuticals and Research LLP | A non-aqueous suspension of anticancer agent |
| PE20250003A1 (es) | 2022-04-22 | 2025-01-07 | Univ Heidelberg | Composicion que comprende analogos de citidina y usos y metodos de la misma |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH527207A (de) | 1968-05-08 | 1972-08-31 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen |
| DE2012888C3 (de) * | 1970-03-14 | 1981-04-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden |
| DE2105468A1 (en) | 1970-04-23 | 1971-11-18 | Czeskoslovenska akademie ved, Prag; VtnKarstedt, E., Dipl.-Ing. Dr., Pat-Anw., 4200 Oberhausen | 1-glycosyl-5-aza-cytosines prepn |
| US4022889A (en) | 1974-05-20 | 1977-05-10 | The Upjohn Company | Therapeutic compositions of antibiotic U-44,590 and methods for using the same |
| US4477442A (en) | 1978-12-12 | 1984-10-16 | The Upjohn Company | Composition of matter and process |
| US4684630A (en) * | 1983-08-24 | 1987-08-04 | Repta Arnold J | Method of parenterally delivering drugs and related compositions |
| JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
| IL77186A0 (en) | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
| DE3712786A1 (de) | 1987-04-15 | 1988-11-03 | Merck Patent Gmbh | Verfahren und mittel zur bestimmung von nucleinsaeuren |
| CS269077B1 (cs) | 1987-10-01 | 1990-04-11 | Piskala Alois | Způsob přípravy 5-azacytosinů |
| US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| US5736531A (en) * | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
| ES2160579T3 (es) | 1991-07-05 | 2001-11-16 | Pro Neuron Inc | Tratamiento de la toxicidad de un agente quimioterapeutico y un agente antivirico con nucleosidos de pirimidina acilados. |
| JPH05219974A (ja) | 1992-02-13 | 1993-08-31 | Mitsui Petrochem Ind Ltd | トロパンアルカロイドの製造方法 |
| US5654286A (en) * | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
| WO1994026761A1 (en) | 1993-05-14 | 1994-11-24 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| GB9311252D0 (en) | 1993-06-01 | 1993-07-21 | Hafslund Nycomed As | Cell growth regualtors |
| US5856090A (en) * | 1994-09-09 | 1999-01-05 | The Scripps Research Institute | DNA-methylase linking reaction |
| US5700640A (en) * | 1994-09-16 | 1997-12-23 | Basf Aktiengesellschaft | Inducers of gamma globin gene expression and screening assays therefor |
| US20030104576A1 (en) | 1994-10-07 | 2003-06-05 | Jonathan W. Nyce | Dna construct, composition, formulations & methods for making the construct & for modulating expression |
| US5856094A (en) | 1995-05-12 | 1999-01-05 | The Johns Hopkins University School Of Medicine | Method of detection of neoplastic cells |
| CA2221411A1 (en) | 1995-05-19 | 1996-11-21 | Phytera, Inc. | Manipulation of plant cell and tissue cultures |
| AU706026B2 (en) | 1995-06-06 | 1999-06-10 | Case Western Reserve University | Myogenic differentiation of human mesenchymal stem cells |
| SG80553A1 (en) | 1995-07-20 | 2001-05-22 | Tanabe Seiyaku Co | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
| KR19990076695A (ko) | 1995-12-22 | 1999-10-15 | 리차드 알. 이킨 | 시티딘 데아미나제 혹은 데옥시시티딘 데아미나제의 과발현과연관된 질병들을 치료하기 위한 활성제_및 방법 |
| AU4753397A (en) | 1996-10-03 | 1998-04-24 | Incyte Pharmaceuticals, Inc. | Methods for generating and analyzing transcript markers |
| IL129126A0 (en) | 1996-10-16 | 2000-02-17 | Icn Pharmaceuticals | Monocyclic l-nucleosides analogs and uses thereof |
| CA2276306C (en) | 1996-12-30 | 2009-12-15 | The Johns Hopkins University School Of Medicine | Loss of imprinting-based in vitro diagnostic method to determine the propensity to develop cancer |
| US6423692B2 (en) | 1997-04-24 | 2002-07-23 | Dana-Farber Cancer Institute, Inc. | Method of enhancing the effectiveness of DCK phosphorylated molecules |
| GB9710995D0 (en) | 1997-05-28 | 1997-07-23 | Marie Curie Research Inst | Tumour suppressor locus and gene at 9q32-33 |
| DK1030839T3 (da) * | 1997-11-10 | 2004-05-03 | Searle & Co | Anvendelse af alkylerede iminosukkere til behandling af multidrugresistens |
| AU5128999A (en) | 1998-07-24 | 2000-02-14 | Yeda Research And Development Co. Ltd. | Prevention of metastasis with 5-aza-2'-deoxycytidine |
| ATE275956T1 (de) | 1998-10-19 | 2004-10-15 | Methylgene Inc | Veränderung der dns methyltransferase durch kombinationstherapie |
| WO2000040269A2 (en) | 1999-01-05 | 2000-07-13 | Lee Clarence C | Pharmaceutical compositions for treatment of diseased tissues |
| EP1176864A2 (en) | 1999-03-18 | 2002-02-06 | The University of Chicago | Chemical and physical treatment that stimulate recombination |
| AU4347500A (en) | 1999-04-13 | 2000-11-14 | Rutgers, The State University Of New Jersey | Ubiquitin cross-reactive protein as a prognostic marker for tumor cell chemosensitivity |
| EP1218036A4 (en) | 1999-09-22 | 2005-01-19 | Ortho Mcneil Pharm Inc | CELL-BASED PROOF |
| WO2001069262A1 (en) | 2000-03-15 | 2001-09-20 | University Of Massachusetts | ERβ-MEDIATED GENE EXPRESSION |
| AU2001247649A1 (en) | 2000-03-21 | 2001-10-30 | Atherogenics, Inc | N-substituted dithiocarbamates for the treatment of biological disorders |
| AUPQ980600A0 (en) | 2000-09-01 | 2000-09-21 | Bionomics Limited | Tumour suppressor gene |
| CN1460181A (zh) | 2000-09-08 | 2003-12-03 | 汉城国立大学工业基金会 | 参与细胞衰老的核酸序列和蛋白质 |
| US20020136709A1 (en) | 2000-12-12 | 2002-09-26 | Nucleus Remodeling, Inc. | In vitro-derived adult pluripotent stem cells and uses therefor |
| US20030165864A1 (en) | 2001-01-16 | 2003-09-04 | Lasek Amy W. | Genes regulated by DNA methylation in tumor cells |
| WO2002057425A2 (en) | 2001-01-22 | 2002-07-25 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| JP2002223753A (ja) | 2001-01-30 | 2002-08-13 | Hitachi Ltd | 薬物応答解析用オリゴヌクレオチドアレイ |
| DE60207043T2 (de) | 2001-02-05 | 2006-07-13 | Innoventus Project Ab | Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| AU2002252183A1 (en) | 2001-03-06 | 2002-09-19 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| US20030013099A1 (en) | 2001-03-19 | 2003-01-16 | Lasek Amy K. W. | Genes regulated by DNA methylation in colon tumors |
| US20060194275A1 (en) | 2001-04-13 | 2006-08-31 | Incyte Corporation | Transporter and ion channels |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| WO2002087586A1 (en) | 2001-04-26 | 2002-11-07 | Control Delivery Systems, Inc. | Sustained release drug delivery system containing codrugs |
| JP2002370939A (ja) | 2001-06-12 | 2002-12-24 | Taisho Pharmaceut Co Ltd | 育毛剤 |
| WO2003006950A2 (en) | 2001-07-12 | 2003-01-23 | Geron Corporation | Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
| SE518759C2 (sv) | 2001-07-27 | 2002-11-19 | Geneinvent Bbl Ab | Vektorer motståndskraftiga mot metylering |
| US20030045497A1 (en) * | 2001-07-27 | 2003-03-06 | Geneinvent Bbl Ab | Methylation resistant vectors |
| WO2003012085A1 (en) | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| WO2003011209A2 (en) | 2001-07-31 | 2003-02-13 | Yeda Research And Development Co. Ltd. | Methods of sensitizing hepatocyte cell cultures to hepatitis infection, beads coated with hbv or hcv polypeptides and methods of using such beads to model viral infection or deliver substances into hepatocytes |
| IN2014DN10834A (https=) * | 2001-09-17 | 2015-09-04 | Psivida Inc | |
| AU2002330088B2 (en) | 2001-09-24 | 2009-09-03 | Jessie L.-S. Au | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy |
| AU2002342004A1 (en) | 2001-10-05 | 2003-04-22 | Case Western Reserve University | Methods and compositions for detecting colon cancers |
| US7132587B2 (en) | 2001-11-08 | 2006-11-07 | Agency Of Industrial Science And Technology | Non-autonomous transposon gene of rice, transformed plant and method of use |
| YU44404A (sh) | 2001-11-23 | 2006-08-17 | Chugai Seiyaku Kabushiki Kaisha | Postupak za identifikovanje ciljnih enzima tumora |
| RU2313365C2 (ru) | 2001-11-29 | 2007-12-27 | Дандрит Байотек А/С | Фармацевтическая композиция для индукции иммунной реакции у человека |
| US20050080027A1 (en) | 2001-11-30 | 2005-04-14 | Markus Horer | Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors |
| US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| US20030147813A1 (en) | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
| WO2003077902A1 (en) * | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| EP1497462A4 (en) | 2002-03-07 | 2007-11-07 | Univ Johns Hopkins Med | GENOMIC SCREEN ON EPIGENETIC MUTED CANCER ASSOCIATED GENES |
| IL163732A0 (en) | 2002-03-07 | 2005-12-18 | Univ Johns Hopkins | Genomic screen for epigenetically silenced tumor suppressor genes |
| CA2481239A1 (en) | 2002-04-05 | 2003-10-23 | University Of Utah Research Foundation | Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2 |
| EP1497447A4 (en) | 2002-04-12 | 2006-09-20 | Univ Missouri | US ECIST MICROARRAYSES FOR DUAL SCREENING OF DNA HYPERMETHYLATION AND GENE INACTIVATION, AND FOR USE IN AN INTEGRATED SYSTEM FOR EVALUATING GENE EXPRESSION, DNA METHYLATION AND ACETYLATION OF HISTONE |
| JP2003310293A (ja) | 2002-04-26 | 2003-11-05 | Mitsui Chemicals Inc | ヌクレオシド化合物の製造法 |
| US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| US20040053304A1 (en) | 2002-06-05 | 2004-03-18 | Case Western Reserve University | Methods and compositions for detecting cancers |
| WO2004009023A2 (en) | 2002-07-18 | 2004-01-29 | University Of Utah Research Foundation | Novel inhibitors of ubiquitin isopeptidases |
| US20050059682A1 (en) | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
-
2002
- 2002-06-05 US US10/164,276 patent/US6982253B2/en not_active Expired - Fee Related
-
2003
- 2003-05-30 CA CA002488108A patent/CA2488108A1/en not_active Abandoned
- 2003-05-30 AU AU2003249680A patent/AU2003249680C9/en not_active Expired
- 2003-05-30 WO PCT/US2003/017293 patent/WO2003103687A1/en not_active Ceased
- 2003-05-30 EP EP03757313A patent/EP1509233A4/en not_active Withdrawn
- 2003-05-30 JP JP2004510806A patent/JP5129922B2/ja not_active Expired - Lifetime
-
2004
- 2004-07-13 US US10/890,621 patent/US7144873B2/en not_active Expired - Lifetime
- 2004-07-13 US US10/890,755 patent/US7135464B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005529163A5 (https=) | ||
| JP5587198B2 (ja) | タキサン誘導体を含有する、安定性が改良された凍結乾燥医薬組成物、及びその製法 | |
| KR101829705B1 (ko) | 안정성이 향상된 주사용 조성물 | |
| US20090062397A1 (en) | Compounds and methods for enhancing solubility of florfenicol and structurally-related antibiotics using cyclodextrins | |
| US20070244166A1 (en) | Pre-mixed, ready-to-use iv bolus compositions and methods of use | |
| DE112016005058T5 (de) | Neue Levothyroxin-Formulierungen zur oralen Anwendung | |
| PT1609481E (pt) | Composições farmacêuticas injectáveis compreendendo diclofenaco de sódio de beta-ciclodextrina e um polissorbato | |
| AU2011273064B2 (en) | Pharmaceutical compositions comprising paracetamol and process for preparing the same | |
| ITMI20010428A1 (it) | Composizioni ad uso inalatorio a base di formoterolo | |
| AU2013377404B2 (en) | Composition of cabazitaxel and sulfobutylether beta-cyclodextrin | |
| AU2019373373A1 (en) | Cyclodextrin-based formulation of a Bcl-2 inhibitor | |
| JP4456177B2 (ja) | 注射剤、注射液および注射用キット製剤 | |
| JP3917820B2 (ja) | オザグレルナトリウム含有注射液およびその安定化方法 | |
| CA2486571C (en) | Pharmaceutical composition | |
| CA3117511C (en) | Cyclodextrin-based formulation of a bcl-2 inhibitor | |
| JP2025522933A (ja) | メルファランを含む安定した液体医薬組成物 | |
| JP2025537030A (ja) | 高濃度のオピランセリンを含む医薬組成物 | |
| WO2018109731A1 (en) | Pharmaceutical compositions of taxane and its derivatives | |
| KR20180003413A (ko) | 오셀타미비어 함유 경구용 고형제제 및 그 제조방법 |